Curriculum Vitae
Younis Baqi
Curriculum Vitae
1– PERSONAL INFORMATION
NAME
Younis Baqi
DATE OF APPOINTMENT
23/01/2012
EMPLOYMENT ID
10065
GRADE
C
FIELD
Chemistry
SPECIALIZATION
Pharmaceutical/Medicinal Chemistry
WEBSITES:
 AGYA
http://agya.info/members/
 GOOGLE SCHOLAR
http://scholar.google.com/citations?user=KJEfqhMAAAAJ&hl=en
 RESEARCH GATE
https://www.researchgate.net/profile/Younis_Baqi
 SCOPUS
http://www.scopus.com/authid/detail.url?origin=resultslist&auth
orId=15049201800&zone
2– EDUCATION & EMPLOYMENT INFORMATION
2.1– EDUCATION
2007 – 2008
Research fellow under supervision of Prof. Dr. E. J. Corey (Nobel prize
laureate for Chemistry (1990)), Department of Chemistry and Chemical
Biology, Harvard University, Cambridge, Massachusetts, USA.
2005 – 2008
PhD in Pharmaceutical/Medicinal Chemistry (summa cum laude) under
the supervision of Prof. Dr. Christa E. Müller, Pharmaceutical Chemistry I,
Pharmaceutical Institute, University of Bonn, Bonn, Germany.
2000 – 2003
MSc in Natural Product Chemistry (very good) under the supervision of
Prof. Dr. Musa H. Abu Zarga, Department of Chemistry, College of
Science, University of Jordan, Amman, Jordan.
1994 – 1998
BSc in Chemistry (very good) from the Dept. of Chemistry, College of
Science, Al-Mustansiriya University, Baghdad, Iraq.
2.2– EMPLOYMENT
2012 – to date
Assistant Professor of Bioorganic and Medicinal Chemistry at Chemistry
Department, College of Science, Sultan Qaboos University, Oman.
2009 – 2012
Lecturer
and
Group
Leader
(assistant
professor)
of
Pharmaceutical/Medicinal Chemistry at the Department of Pharmaceutical
Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany.
2005 – 2008
Teaching & Lab Instructor at the Department of Pharmaceutical
Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany.
2005 – 2005
Researcher assistant in the field of Organic Synthesis at the Institute of
Biochemistry University of Tübingen, Germany.
2002 – 2004
Researcher in the field of Natural Product Chemistry, Department of
Chemistry, College of Science, University of Jordan, Amman, Jordan.
2000 – 2003
Lab Instructor: involved in teaching General Chemistry, Organic
Chemistry-1 and Organic Chemistry-2 Laboratories, Department of
Chemistry, College of Science, University of Jordan, Amman, Jordan.
1|Page
Curriculum Vitae
Younis Baqi
3– AWARDS & RECOGNITION
3.1– AWARDS
(a)
The Arab-German Young Academy of Sciences and Humanities (AGYA) 2014
Certificate, elected as one of the 25 members from Arab academic world, 19th –
25th of June 2014, Berlin, Germany.
(b)
ZukunftErfindenNRW 2013 Award (Inventions for the Future), 14th of January
2013 Essen, Germany, awarded by the Germany Science Minister Svenja Schulze
for the patent entitled: GPR 17 Agonists and Screening Assay. US Patent
20,130,158,093.
(c)
Niederlassungserlaubnis für Hochqualifizierte § 19 (Permanent Residency
Award for Highly Qualified Scientist), 9th of December 2010, Bonn, Germany.
(d)
PHOENIX Pharmazie Wissenschaftspreis 2010 (PHOENIX Pharmaceutical
Science Award), 3rd of November 2010 Erlangen Nürenberg, Germany, for the
paper entitled: High-affinity, non-nucleotide-derived antagonists of platelet P2Y12
receptors, published in The Journal of Medicinal Chemistry 2009, 52, 3784–3793.
(e)
Nature Protocols Front Page Cover Certificate, for the paper entitled: Synthesis
of alkyl- and aryl-amino-substituted anthraquinone derivatives by microwaveassisted copper(0)-catalyzed Ullmann coupling reactions, published in Nature
Protocols 2010, 5, 945–953.
(f)
Best Poster Award International Congress Purines–2010 Adenine Nucleosides and
Nucleotides in Medicine, 30th of May – 2nd of June 2010 Tarragona-Bercelona, Spain,
for the poster entitled: Discovery of the first potent P2X2 receptor antagonists.
(g)
Bioorganic & Medicinal Chemistry Letters Most Cited Paper 2006–2009
Award, for the paper entitled: Polyoxometalates–a new class of potent ectonucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors, published in
Bioorganic & Medicinal Chemistry Letters 2006, 16, 5943–5947.
(h)
Oral Communication Award Third Joint Italian-German Purine Club Meeting
Purinergic Receptors: New Frontiers for Novel Therapies, July 17 th – 20th, 2009
Camerino, Italy, for the talk entitled: Characterisation of a new, very potent non–
nucleotide antagonist acting at the human platelet P2Y 12-receptor and identification
of its molecular site of interaction.
(i)
Visiting Scholar Award, Deutsche Forschungsgemeinschaft (DFG) (German
Research Foundation), GRK-804, Harvard University, Cambridge, USA, 2007–2008.
3.2– RECOGNITION
(a)
Editorial Board Member of the international journal: Mini-Reviews in Medicinal
Chemistry, since 2016.
(b)
Invited to write a review article in the international journal: Drug Discovery Today
(IF = 6.691), 2016.
(c)
Invited to present a talk in the international purines conference, Hamburg, July 23–
25, 2015.
(d)
Invited to write a review article in the international journal: Mini-Reviews in
Medicinal Chemistry (IF = 3.186), published in 2015.
(e)
Elected member of the Arab-German Young Academy of Science and Humanities
(AGYA), since 2014.
(f)
Invited to participate in the 2nd symposium of The Arab-American Frontiers of
Science, Engineering, and Medicine, December 13-15, 2014, Muscat, Oman.
2|Page
Curriculum Vitae
Younis Baqi
(g)
Invited to participate in the Qatar Foundation Annual Research Conference 2014
(ARC’14), November 18–19, 2014 along with the AGYA Conference November 2022, 2014, Doha, Qatar.
(h)
Invited to give a keynote talk in the 4th International Conference of Young Scientists
– Chemistry Today (ICYS–2014), August 18–22, Yerevan, Armenia, 2014.
(i)
Invited to Chair a Symposium “Medicinal Chemistry and Drug Development I: P1Receptor Ligands and Ecto-5’-Nucleotidase Inhibitors” at the Purines 2014
international conference.
(j)
Invited to join the local organizing team at the Purines 2014 international
conference in Bonn Germany.
3.3– SCHOLARSHIP & STUDY AWARDS
(a)
Full PhD Award, Deutscher Akademischer Austausch Dienst (DAAD), University of
Bonn, Bonn, Germany, 2005–2008.
(b)
German Language Course Award, Deutscher Akademischer Austausch Dienst
(DAAD), Goethe Institute, Mannheim, Germany, 2004–2005.
(c)
Full MSc Award, Iraqi–Jordanian Academic Cultural Exchange, the University of
Jordan, Amman, Jordan, 2000–2003.
3.4– MEMBERSHIP & FELLOWSHIP
(a)
Member of the Arab-German Young Academy of Science and Humanities (AGYA)
working groups: (i) Energy, Water and Environment, (ii) Innovation, & (iii) Arab –
German Education, since 2014.
(b)
Member (collegiate) of the “Bonner Forum Biomedizin” (BFB), since 2010.
(c)
Group Leader Fellow within the EU-funded ERANET-Neuron project “Synthesis and
Validation of Novel Parkinson Therapeutics with Activity on Heterodimeric G ProteinCoupled Receptors” at the PharmaCenter Bonn, 2008–2009.
(d)
Visiting Scholar Fellow to the Department of Chemistry and Chemical Biology,
Harvard University, Cambridge, Massachusetts, USA, 2007–2008.
(e)
Member of the “German Purine Club”, since 2007.
(f)
Member (collegiate) of the research training group (GRK 804) “Analysis of the
cellular functions by combinatorial chemistry and biochemistry”, 2006–2012.
(g)
Member of the Iraqi Chemists Union since 1998.
4– TEACHING
4.1– INSTRUCTION AND PROJECT SUPERVISION
2012 – present
(a)
Lecturing in the field of Bioorganic and Medicinal Chemistry at
Sultan Qaboos University, Muscat, Oman:
At SQU
So far I have taught 13 different courses:
i.
Lecture based courses:
1.
General Chemistry for Engineers (CHEM1071) (SP014, 129
students).
2.
General Chemistry I (CHEM2101) (F014, SP015 & F015: 84,
80 & 91 students, respectively).
3|Page
Curriculum Vitae
Younis Baqi
3.
General Chemistry II (CHEM2102) (S012: 43 & 51 students).
4.
Organic Chemistry for Health Sciences (CHEM3327) (SP012, 9
students).
5.
Industrial Organic Chemistry (CHEM4470) (F012, F013, F014,
F015: 15, 17, 21 & 16 students, respectively).
6.
Fine Chemicals (CHEM4472) (F012, F013: 13 & 22 students,
respectively).
7.
Essentials of Biological Chemistry (CHEM4477) (SP014, 7
students).
8.
Chemistry for Teachers (CHEM4481) (SP012, SP013: 7 & 15
students, respectively).
9.
Chemistry Seminar I (CHEM5591) (SP012, SP013: 9 & 16
students).
ii. Laboratory based courses:
10.
General Chemistry I (CHEM2101) (SP014, SP015: 40, 50 & 61
students).
11.
Organic Chemistry for Health Sciences (CHEM3327) (SP012: 9
students).
12.
Industrial Organic Chemistry (CHEM4470) (F012, F013, F014,
F015: 15, 17, 21 & 16 students, respectively).
13.
Fine Chemicals (CHEM4472) (F012, F013: 13 & 22 students,
respectively).
iii. Training Program Mentored
Mentored Industrial
Chemistry students
Training
(CHEM5001)
for
Applied
iv. MSc Thesis Committee Member at SQU
Member of the thesis committee for Thuraya Salim Al
Harthy (52892), (degree awarded on November 2013),
MSc Thesis: Synthesis and anti-tumor activity of 5-fluoro-2methyl-6-(-4-(substituted phenyl)piprazin-1-yl)benzoxazoles.
2007 – to date
“Before &
At SQU”
2009 – 2011
(b) Supervising undergraduate students (25 students and 2 are
active), Master students (3 students and 1 is active) and
supervising PhD students (1 student and 1 is active), at Bonn
University in Germany, and at Sultan Qaboos University in
Oman.
(c)
Lecturing
&
Group
leader
in
the
field
of
Medicinal/Pharmaceutical Chemistry at the Department of
Pharmaceutical Chemistry, Pharmaceutical Institute, University
of Bonn, Germany.
4.2– PROJECT SUPERVISION AT SULTAN QABOOS UNIVERSITY
4.2.1– PhD Supervision. Currently Supervising Reem Abdullah Al-Alawi
(81928/2015), PhD Thesis: Investigating the anti-cancer properties of
natural products isolated from date fruits of the Omani elite variety "Khalas".
4|Page
Curriculum Vitae
Younis Baqi
4.2.3– Undergraduate Supervision at SQU
Final Year Project (CHEM5000)
Entry
Semester
Student Name, ID & Project Title
(From – To)
1
FL12 – SP13
Iman Khalifa Salim Al Sawafi, (85479) "Synthesis of Some
Novel Substituted N-Benzylideneaniline Derivatives"
2
FL12 – SP13
Samah Khalifah Al-Mamari, (87374) "Synthesis
Characterization of N–Benzylideneaniline Derivatives"
3
FL13 – SP14
Sara Salim Hamed Al Busaidi, (90197) "Synthesis of Imine
Resveratrol Analogues"
4
FL13 – SP14
Intisar Nasser Salim Nasser Al Mugheiri, (89851) "Synthesis
of Some Resveratrol Derivatives"
5
FL14 – SP15
Jawhara Hamed Ali Al Mashaiqri, (94259) "Preparation of
Different Extracts from Date Palm Tree (Phoenix Dactylifera
L.) of Variety “Khalas” Using Polar Solvents"
6
FL14 – SP15
Jawaher Salim Mohammed Al Nadabi, (94400) “Preparation
and Fractionation of Organic Solvents Extracts from Date
Palm Fruits (Phoenix Dactylifera L.) of the Omani Variety
"Khalas"
7
FL15 – SP16
Currently Supervising Mohammed Al Jassasi, (93908)
“Synthesis and Characterization of Xanthine Derivatives as
Novel Adenosine A2A Receptor Antagonists”
8
FL15 – SP16
Currently Supervising Mohammed Al Mahrezi, (97809)
“Synthesis and Characterization of Caffeine Derivatives as
Adenosine A2A Receptor Antagonists”
9
SP16 – FL16
Currently Supervising Mansouri Al Maamari, (92845)
“Synthesis and Characterization of New Adenosine Receptor
Antagonists based on Caffeine Scaffold”
and
Voluntarily Project Supervision for Applied Chemistry Students
10
FL13 – SP14
Ahmed Matar Mohammed Al Rubkhi (090561) “Preparation
and TLC analysis of Water and Butanol Extracts from Omani
“Khalas” Date Fruits
11
FL13 – SP14
Said Salim Harib Al Shekaili (090872) “Preparation and TLC
analysis of Ethanol Extracts from Omani “Khalas” Date Fruits
12
FL14 – SP15
Zakariya Mohamed Ahmed Abdulmohsen Al Lawati (88744)
“Preparation and TLC analysis of Ethyl Acetate Extracts from
Omani Date Fruits (Phoenix Dactylifera L.) Type "Khalas"
13
FL14 – SP15
Ridha Yousuf Darwish Al Ajmi (93231) “Preparation and TLC
analysis of Acetone Extracts from Omani “Khalas” Date Fruits
4.3– INTERNATIONAL CO-SUPERVISION
4.3.1– MSc Co-Supervision. Currently Co-Supervising Ahmed Hussain Ismail,
Chemistry Department, Al-Mustansiriya University, Baghdad, Iraq. MSc
Thesis: Synthesis, characterization and biological evaluation of new
heterocyclic compounds from chalcone derivatives.
5|Page
Curriculum Vitae
Younis Baqi
4.3.2– PhD Co-Supervision. Co-supervised Enas Mustafa Malik (degree
awarded on August 2015), Department of Pharmaceutical Chemistry,
University of Bonn, Germany. PhD Thesis: Synthetic access to novel
anthraquinone derivatives, biological evaluation, and analysis of structureactivity relationships at P2Y receptors.
4.4– CURRICULUM DEVELOPMENT AND TEACHING MANAGEMENT
2012 – present
At SQU
New Courses:
(a)
Developed a new 3 credit core course "Essentials of Biological
Chemistry" (CHEM4477).
This course played an important role for the Canadian
accreditation of our Chemistry Department, which we
recently accredited for the period of 2015–2019.
(b)
Lab Manuals
Developed lab manuals for two core courses in the Applied
Chemistry degree: Industrial Organic Chemistry (CHEM4470)
& Fine Chemicals (CHEM4472)
(c)
Ongoing Development in the Applied Chemistry Degree Plan
Major changes in the Applied Chemistry degree plan is
approved by the chemistry department board, including:
i.
Fundamental of Industrial Chemistry (CHEM4475), 4
credit core course.
ii.
Project for Applied Chemistry (CHEM5002), 3 credit
core course.
iii.
Fine Chemicals (CHEM4472), 3 credit elective course.
(d)
Member of Education & Learning working group within AGYA.
For more details please visit: http://agya.info/workinggroups/arab-and-german-education/
(e)
Invited to participate in the Arab–German Education &
Learning Workshop, Manama, Bahrain, 2015.
(f)
Lab Management of CHEM2101: I am involved in coordination
of the laboratory of CHEM2101 since F014.
4.5– STUDENT ADVISING
2012 – present
(a)
Applied Chemistry major 2012 & 2013 cohorts (18 students).
At SQU
(b)
Pre-major College of Science 2013 cohort (22 students).
(c)
Advised and mentored several students in choosing their
postgraduate studies abroad.
4.6– TEACHING ACTIVITIES OUTSIDE THE CLASSROOM
2012 – present
(a)
Conducting industrial visits for chemistry students. Visiting
some industrial sectors in F012 & F013.
2007 – 2011
(b)
Conducting chemistry workshops for non-chemist students.
(c)
Supervising school students in university chemistry labs.
Students belongs to several high schools from Germany.
6|Page
Curriculum Vitae
Younis Baqi
5– SCHOLARLY ACHIEVEMENTS
5.1–
REFEREED JOURNAL PAPERS
1.
Podurgiel, S.J.; Spencer, T.; Kovner, R.; Baqi, Y.; Müller, C.E.; Correa, M.;
Salamone, J.D.Induction of oral tremor in mice by the acetylcholinesterase inhibitor
galantamine: Reversal with adenosine A2A antagonism. Pharmacol. Biochem. Behav.
2016, 140, 62–67.
2.
Laurent, C.; Burnouf, S.; Ferry, B.; Batalha, V.L.; Coelho, J.E.; Baqi, Y.; Malik, E.;
Mariciniak, E.; Parrot, S.; Van der Jeugd, A.; Faivre, E.; Flaten, V.; Ledent, C.;
D’Hooge, R.; Sergeant, N.; Hamdane, M.; Humez, S.; Müller, C.E.; Lopes, L.V.
Buée, L.; Blum, D. A2A adenosine receptor deletion is protective in a mouse model of
Tauopathy. Mol. Psychiatr. 2016, 21, 97–107.
3.
Baqi, Y.* Ecto-nucleotidase inhibitors: recent development in drug discovery. MiniRev. Med. Chem. 2015, 15, 21–33.
4.
Malik, E.M.; Baqi, Y.*; Müller, C.E. Syntheses of 2-substituted 1-amino-4-bromoanthraquinones (bromaminic acid analogues) – precursors for dyes and drugs.
Beilstein J. Org. Chem. 2015, 11, 2326–2333.
5.
Zhang, Y.; Peti-Peterdi, J.; Müller, C.E.; Carlson, N.G.; Baqi, Y.; Strasburg, D.L.;
Heiney, K.M.; Villanueva, K.; Kohan, D.E.; Kishore, B.K. P2Y 12 Receptor Localizes in
the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action
and Alleviates Nephrogenic Diabetes Insipidus. J. Am. Soc. Nephrol. 2015, 26,
2978–2987.
6.
Paoletta, S.; Sabbadin, D.; von Kügelgen, I.; Hinz, S.; Katritch, V.; Hoffmann, K.;
Abdelrahman, A.; Strassburger, J.; Baqi, Y.; Zhao, Q.; Stevens, R.C.; Moro, S.;
Müller, C.E.; Jacobsona, K.A. Modeling Ligand Recognition at the P2Y12 Receptor in
Light of X-Ray Structural Information. J. Comput. Aided Mol. Des. 2015, 29, 737–
756.
7.
Fuzzati-Armentero, M.T.; Cerri, S.; Levandis, G.; Ambrosi, G.; Montepeloso, E.;
Antoninetti, G.; Blandini, F.; Baqi, Y.; Müller, C.E.; Volpini, R.; Costa, G.; Simola,
N.; Pinna, A. Dual target strategy: combining distinct non-dopaminergic treatments
reduces neuronal cell loss and synergistically modulates l-DOPA-induced rotational
behavior in a rodent model of Parkinson's disease. J. Neurochem. 2015, 134, 740–
747.
8.
Kaster, M.P.; Machado, N.J.; Silva, H.B.; Nunes, A.; Ardais, A.P.; Santana, M.; Baqi,
Y.; Müller, C.E.; Rodrigues, A.L.; Porciúncula, L.O.; Chen, J.F.; Tomé, Â.R.;
Agostinho, P.; Canas, P.M.; Cunha, R.A. Caffeine acts through neuronal adenosine
A2A receptors to prevent mood and memory dysfunction triggered by chronic stress.
Proc. Natl. Acad. Sci. U.S.A. 2015, 112, 7833–7838.
9.
Fiene, A.; Baqi, Y.; Lecka, J.; Sévigny, J.; Müller, C.E. Fluorescence polarization
immunoassays for monitoring nucleoside triphosphate diphosphohydrolase
(NTPDase) activity. Analyst 2015, 140, 140–148.
10.
Yohn, S.E.; Thompson, C.; Randall, P.A.; Christie A. Lee, C.A.; Müller, C.E.; Baqi,
Y.; Correa, M.; Salamone, J.D. The VMAT-2 inhibitor tetrabenazine alters effortrelated decision making as measured by the T-maze barrier choice task: reversal
7|Page
Curriculum Vitae
Younis Baqi
with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker
bupropion. Psychopharmacology 2015, 232, 1313–1323.
11.
Baqi, Y.*; Alshaibani, S.; Ritter, K.; Abdelrahman, A.; Spinrath, A.; Kostenis, E.;
Müller, C.E. Improved synthesis of 4-/6-substituted 2-carboxy-1H-indole-3-propionic
acid derivatives and structure–activity relationships as GPR17 agonists.
MedChemComm, 2014, 5, 86–92.
12.
Hoffmann, K.; Lutz, D.A.; Straßburger, J.; Baqi, Y.; Müller, C.E.; von Kügelgen, I.
Competitive mode and site of interaction of ticagrelor at the human platelet P2Y 12receptor. J. Thromb. Haemost. 2014, 12, 1898–1905.
13.
Zebisch, M.; Baqi, Y.; Schäfer, P.; Müller, C.E.; Sträter, N. Crystal structure of
NTPDase2 in complex with the sulfoanthraquinone inhibitor PSB-071. J. Struct. Biol.
2014, 185, 336–341.
14.
Jerónimo-Santos, A.; Batalha, V.L.; Müller, C.E.; Baqi, Y.; Sebastião, A.M.; Lopes,
L.V.; Diógenes, M.J. Impact of in vivo chronic blockade of adenosine A 2A receptors
on the BDNF-mediated facilitation of LTP. Neuropharmacology 2014, 83, 99–106.
15.
Horváth, G.; Gölöncsér, F.; Csölle, C.; Király, K.; Andó, R.D.; Baranyi, M.; Koványi,
B.; Máté, Z.; Hoffmann, K.; Algaier, I.; Baqi, Y.; Müller, C.E.; Von Kügelgen, I.;
Sperlágh, B. Central P2Y12 receptor blockade alleviates inflammatory and
neuropathic pain and cytokine production in rodents. Neurobiol. Dis. 2014, 70C,
162–178.
16.
Cerri, S.; Levandis, G.; Ambrosi, G.; Montepeloso, E.; Antoninetti, G.F.; Franco, R.;
Lanciego, J.L.; Baqi, Y.; Müller, C.E.; Pinna, A.; Blandini, F.; Armentero, M.T.
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor
antagonists in an animal model of Parkinson disease. J. Neuropathol. Exp. Neurol.
2014, 73, 414–24.
17.
Randall, P.A.; Lee, C.A.; Nunes, E.J.; Yohn, S.E.; Nowak, V.; Khan, B.; Shah, P.;
Pandit, S.; Vemuri, V.K.; Makriyannis, A.; Baqi, Y.; Müller, C.E.; Correa, M.;
Salamone, J.D. The VMAT-2 inhibitor tetrabenazine affects effort-related decision
making in a progressive ratio/chow feeding choice task: reversal with antidepressant
drugs. PLoS–One 2014, 9, e99320.
18.
Sassi, Y.; Ahles, A.; Truong, D.-J.J.; Hulot, J.-S.; Baqi, Y.; Lee, S.-Y.; Müller, C.E.;
Husse, B.; Dendorfer, A.; Laggerbauer, B.; Engelhardt, S. Paracrine actions of the
intracellular second messenger cAMP secreted from cardiac myocytes. J. Clin. Invest.
2014, 124, 5385–5397.
19.
Pinna, A.; Bonaventura, J.; Farré, D.; Sánchez, M.; Simola, N.; Mallol, J.; Lluís, C.;
Costa, G.; Baqi, Y.; Müller, C.E.; Cortés, A.; McCormick, P.; Canela, E.I.; MartínezPinilla, E.; Lanciegoc, J.L.; Casadó, V.; Armenterog, M.-T.; Franco, R. L-DOPA
disrupts adenosine A2A–cannabinoid CB1–dopamine D2 receptor heteromer cross-talk
in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies. Exp.
Neurol. 2014, 253, 180–191.
20.
Nunes, E.J.; Randall, P.A.; Estrada, A.; Epling, B.; Hart, E.E.; Lee, C.A.; Baqi, Y.;
Müller, C.E.; Correa, M.; Salamone, J.D. Effort-related motivational effects of the
pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio
5/ chow feeding choice task. Psychopharmacology 2014, 231, 727–736.
8|Page
Curriculum Vitae
Younis Baqi
21.
Podurgiel, S.J.; Nunes, E.J.; Yohn, S.E.; Barber, J.; Thompson, A.; Milligan, M.; Lee,
C.A.; López-Cruz, L.; Pardo, M.; Valverde, O.; Lendent, C.; Baqi, Y.; Müller, C.E.;
Correa, M.; Salamone, J.D. The vesicular monoamine transporter (VMAT-2) inhibitor
tetrabenazine induces tremulous jaw movements in rodents: Implications for
pharmacological models of parkinsonian tremor. Neuroscience 2013, 250, 507–519.
22.
Nunes, E.J.; Randall, P.A.; Hart, E.E.; Freeland, C.; Yohn, S.E.; Baqi, Y.; Müller,
C.E.; López-Cruz, L.; Correa, M.; Salamone, J.D. Effort-related motivational effects
of the VMAT-2 inhibitor tetrabenazine: Implications for animal models of the
motivational symptoms of depression. J. Neurosci. 2013, 33, 19120-19130.
23.
Silva, C.G.; Métin, C.; Fazeli, W.; Machado, N.J.; Darmopil, S.; Launay, P.-S.;
Ghestem, A.; Nesa, M.-P.; Bassot, E.; Szabó, E.; Baqi, Y.; Müller, C.E.; Tomé, A.R.;
Ivanov, A.; Isbrandt, D.; Zilberter, Y.; Cunha, R.A.; Esclapez, M.; Bernard, C.
Adenosine receptor antagonists including caffeine alter fetal brain development in
mice. Sci. Transl. Med. 2013, 5, 197ra104.
24.
Collins–Praino, L.E.; Paul, N.E.; Ledgard, F.; Podurgiel, S.J.; Kovner, R.; Baqi, Y.;
Müller, C.E., Senatus, P.B.; Salamone, J.D. Deep brain stimulation of the
subthalamic nucleus reverses oral tremor in pharmacological models of
parkinsonism: interaction with the effects of adenosine A 2A antagonism. Eur. J.
Neurosci. 2013, 38, 2183–2191.
25.
Pardo, M.; López-Cruz, L.; Valverde, O.; Ledent, C.; Baqi, Y.; Müller, C.E.;
Salamone, J.D.; Correa, M. Effect of subtype-selective adenosine receptor
antagonists on basal or haloperidol-regulated striatal function: studies of exploratory
locomotion and c-Fos immunoreactivity in outbred and A 2A R KO mice. Behav. Brain
Res. 2013, 247, 217–226.
26.
Batalha, V.L.; Pego, J.M.; Fontinha, B.M.; Costenla, A.R.; Valadas, J.S.; Baqi, Y.;
Radjainia, H. Müller, C.E. Sebastião, A.M.; Lopes, L.V. Adenosine A(2A) receptor
blockade reverts hippocampal stress-induced deficits and restores corticosterone
circadian oscillation. Mol. Psychiatr. 2013, 18, 320–331.
27.
Salamone, J.D.; Collins-Praino, L.E.; Pardo, M.; Podurgiel, S.J.; Baqi, Y.; Müller,
C.E.; Schwarzschild, M.A.; Correa, M. Conditional neural knockout of the adenosine
A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced
tremulous jaw movements: Studies with a mouse model of parkinsonian tremor.
Eur. Neuropsychopharmacol. 2013, 23, 972–977.
28.
Baqi, Y.*; Müller, C.E. Efficient and mild deamination procedure for 1aminoanthraquinones yielding a diverse library of novel derivatives with potential
biological activity. Tet. Lett. 2012, 53, 6739–6742.
29.
Baqi, Y.; Müller, C.E. Convergent synthesis of the potent P2Y receptor antagonist
MG 50-3-1 based on a regioselective Ullmann coupling reaction. Molecules 2012,
17, 2599–2615.
30.
Randall, P.A.; Pardo, M.; Nunes, E.J.; López Cruz, L.; Vemuri, V.K.; Makriyannis, A.;
Baqi, Y.; Müller, C.E.; Correa, M.; Salamone, J.D. Dopaminergic modulation of
effort-related choice behavior as assessed by a progressive ratio chow feeding choice
task: pharmacological studies and the role of individual differences. PLoS–One
2012, 7, e47934.
9|Page
Curriculum Vitae
Younis Baqi
31.
Müller, C.E.; Schiedel, A.C.; Baqi, Y. Allosteric modulators of rhodopsin-like G
protein-coupled receptors: Opportunities in drug development. Pharmacol. Ther.
2012, 135, 292–315.
32.
Santerre, J.L.; Nunes, E.J.; Kovner, R.; Leser, C.E.; Randall, P.A.; Collins-Praino,
L.E.; Lopez Cruz, L.; Correa, M.; Baqi, Y.; Müller, C.E.; Salamone, J.D. The novel
adenosine A(2A) antagonist prodrug MSX-4 is effective in animal models related to
motivational and motor functions. Pharmacol. Biochem. Behav. 2012, 102, 477–
487.
33.
Hildenbrand, S.; Baqi, Y.; Müller, C.E. Synthesis of tritium-labeled levetiracetam
((2S)-2-(2-oxopyrrolidin-1-yl) butanamide) with high specific activity. J. Label.
Compd. Radiopharm. 2012, 55, 48–51.
34.
Pardo, M.; Lopez-Cruz, L.; Valverde, O.; Ledent, C.; Baqi, Y.; Müller, C.E.;
Salamone, J.D.; Correa, M. Adenosine A2A receptor antagonism and genetic deletion
attenuate the effects of dopamine D2 antagonism on effort-based decision making in
mice. Neuropharmacology 2012, 62, 2068–2077.
35.
Baqi, Y.; Hausmann, R.; Rosefort, C.; Rettinger, J.; Schmalzing, G.; Müller, C.E.
Discovery of potent competitive antagonists and positive modulators of the P2X2
receptor. J. Med. Chem. 2011, 54, 817–830.
36.
Collins, L.E.; Paul, N.E.; Abbas, S.F.; Leser, C.E.; Podurgiel, S.J.; Galtieri, D.J.;
Chrobak, J.J.; Baqi, Y.; Müller, C.E.; Salamone, J.D. Oral tremor induced by
galantamine in rats: a model of the parkinsonian side effects of cholinomimetics
used to treat Alzheimer's disease. Pharmacol. Biochem. Behav. 2011, 99, 414–122.
37.
Randall, P.A.; Nunes, E.J.; Janniere, S.L.; Stopper, C.M.; Farrar, A.M.; Sager, T.N.
Baqi, Y.; Hockemeyer, J.; Müller, C.E.; Salamone, J.D. Stimulant effects of
adenosine antagonists on operant behavior: differential actions of selective A2A and
A1 antagonists. Psychopharmacology (Berl). 2011, 216, 173–186.
38.
Baqi, Y.*; Müller, C.E. Synthesis of alkyl- and aryl-amino-substituted anthraquinone
derivatives by microwave-assisted copper(0)-catalyzed Ullmann coupling reactions.
Nat. Protoc. 2010, 5, 945–953.
39.
Baqi, Y.; Lee, S.-Y.; Iqbal, J.; Ripphausen, P.; Lehr, A.; Scheiff, A.B.; Zimmermann,
H.; Bajorath, J.; Müller, C.E. Development of potent and selective inhibitors of ecto5’-nucleotidase based on an anthraquinone scaffold. J. Med. Chem. 2010, 53, 2076–
2086.
40.
Hoffmann, K.; Baqi, Y.; Morena, M.S.; Glänzel, M.; Müller, C.E.; von Kügelgen, I.
Interaction of new, very potent non-nucleotide antagonists with Arg256 of the
human platelet P2Y12 receptor. J. Pharmacol. Exp. Ther. 2009, 331, 648–655.
41.
Baqi, Y.; Atzler, K.; Köse, M.; Glänzel, M.; Müller, C.E. High-affinity, nonnucleotide-derived antagonists of platelet P2Y12 receptors. J. Med. Chem. 2009, 52,
3784–3793.
42.
Baqi, Y.; Giroux, S.; Corey, E.J. A study of the epoxidation of cycloolefins by the
t-BuOH copper-permanganate system. Org. Lett. 2009, 11, 959–961.
43.
Baqi, Y.; Weyler, S.; Iqbal, J.; Zimmermann, H.; Müller, C.E.; Structure-activity
relationships of anthraquinone derivatives derived from bromaminic acid as
10 | P a g e
Curriculum Vitae
inhibitors of ecto-nucleoside triphosphate
Purinergic Signalling 2009, 5, 91–106.
Younis Baqi
diphosphohydrolases
(E-NTPDases).
44.
Weyler, S.; Baqi, Y.; Hillmann, P.; Kaulich, M.; Hunder, A.M.; Müller, I.A.; Müller,
C.E. Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as
non-nucleotide-derived P2Y2 receptor antagonists. Bioorg. Med. Chem. Lett. 2008,
18, 223–227.
45.
Baqi, Y.; Müller, C.E. Catalyst-free microwave-assisted amination of 2-chloro-5nitrobenzoic acid. J. Org. Chem. 2007, 72, 5908–5911.
46.
Baqi, Y.; Müller, C.E. Rapid and efficient microwave-assisted copper(0)-catalyzed
Ullmann coupling reaction: general access for anilinoanthraquinone derivatives. Org.
Lett. 2007, 9, 1271–1274.
47.
Müller, C.E.; Iqbal, J.; Baqi, Y.; Zimmermann, H.; Röllich, A.; Stephan, H.;
Polyoxometalates–a
new
class
of
potent
ecto-nucleoside
triphosphate
diphosphohydrolase (NTPDase) inhibitors. Bioorg. Med. Chem. Lett. 2006, 16,
5943–5947.
48.
Abdel-Jalil, R.J.; Voelter, W.; Maichle-Mossmer, A.; Baqi, Y.; Machulla, H.-J. Crystal
structure of 2-(3-acetyl-1-(4-bromophenyl)-5-((R)-4-chlorophenyl)-1,2,4-triazolo-4yl)-2-deoxy-1,3,4,6-tetraacetyl--D-glucose, C30H31BrClN3O10. Z. Kristallogr.-New
Cryst. Struct. 2006, 221, 463–464.
49.
Al-Noaimi, M.Z.; Abdel-Jalil, R.J.; El-Abadelah, M.M.; Haddad, S.F.; Baqi, Y.;
Voelter, W. Metal-assisted oxidative cyclization of arylamidrazones I. Synthesis of 3acetyl-1,4-dihydro-1-phenyl-1,2,4-benzotriazine. Monatsh. Chem. 2006, 137, 745–
750.
5.2– NON-PEER-REFEREED PUBLICATIONS
50.
Müller, C.E.; Iqbal, J.; Baqi, Y. Kapillarelektrophorese-Nano-Assays
Wirkstofftestung. GIT Labor–Fachzeitschrift 2006, 10, 897–900.
in
der
51.
Müller, C.E.; Iqbal, J.; Baqi, Y. Capillary electrophoresis nano-assays. Novel in vitro
screening methods in the search for future drugs. Screening – Trends in Drug
Discovery 2006, 7, 26–28.
5.3– Conference Abstracts (International & Refereed)
1.
Fiene, A.; Baqi, Y.; Lecka, J.; Sevigny, J.; Muller, C.E. Establishment of novel
fluorescence polarization immunoassay-(FPIA-) based NTPDase assays for highthroughput inhibitor screening. Purinergic Signalling 2014, 10, 752–752.
2.
Malik, E.M.; Baqi, Y.; Fiene, A.; Lecka, J.; Sevigny, J.; Muller, C.E. Design,
synthesis and structure-activity relationship of anthraquinone derivatives as
NTPDase3 inhibitors. Purinergic Signalling 2014, 10, 765–766.
3.
Spanier, C.; Baqi, Y.; Malik, E.M.; Hausmann, R.; Müller, C.E. Structure-activity
relationships of anthraquinone derivatives as modulators of P2X3 receptors
Purinergic Signalling 2014, 10, 778–779.
4.
Rafehi, M.; Baqi, Y.; Malik, E.; Müller, C.E. Anthraquinone derivatives as potent and
selective P2Y4 receptor antagonists. Purinergic Signalling 2014, 10, 782–782.
11 | P a g e
Curriculum Vitae
Younis Baqi
5.
Pillaiyar, T.; Baqi, Y.; Alshaibani, S.; Abdelrahman, A.; Namasivayam, V.; Kostenis,
E.; Müller, C.E. Design, synthesis and structure-activity relationship studies of 4/6substituted 2-carboxy-1H-indole-3-propionic acid derivatives as GPR17 agonists.
Purinergic Signalling 2014, 10, 784–785.
6.
von Kügelgen, I.; Lutz, D.; Straßburger, J.; Baqi, Y.; Müller, C.E.; Hoffmann, K.
Mode and site of interaction of the novel antiplatelet drug ticagrelor at the
recombinant human P2Y12 receptor. The FASEB Journal, 2014, 28, 1057.11.
7.
Bruckner, M.; Schnaars, M.; Baqi, Y.; Mülller, C.E.; Halle, A. Microglial purinergic
receptors in Alzheimer's disease. Purinergic Signalling 2014, 10, 724–725.
8.
Batalha, V.L.; Valdas, J.S.; Baqi, Y.; Radjainia, H.; Müller, C.E.; Lopes, L.V.
Adenosine A2A receptor activation-trigger to aging-like modifications on adenosine
modulation in the hippocampus. J. Neurochem. 2013, 125, 153-153.
9.
Lee, C.A.; Randall, P.A.; Epling, B.; Nunes, E.J.; Baqi, Y.; Msller, C.E.; Correa, M.;
Salamone, J.D. Proinflammatory pharmacological manipulations associated with
depression: Effects of peripheral Lipopolysaccharide administration on effort-related
decision making in operant choice procedures. Society for Neuroscience Abstract
Viewer and Itinerary Planner 2013, 43.
10.
Nunes, E.J.; Hart, E.E.; Estrada, A.; Epling, B.; Randall, P.A.; Lee, C.A.; Baqi, Y.;
Müller, C.E.; Correa, M.; Salamone, J.D. Pro-inflammatory cytokines and
motivational dysfunctions related to depression: Interleukin 1 beta alters effortrelated choice behavior in rats. Society for Neuroscience Abstract Viewer and
Itinerary Planner 2013, 43.
11.
Randall, P.A.; Pandit, S.; Nunes, E.J.; Lee, C.A.; Baqi, Y.; Müller, C.E.; Correa, M.;
Salamone, J.D. Dopamine/adenosine interactions regulate work output on a
progressive ratio/chow feeding choice task: Relevance for the motivational
symptoms of depression. Society for Neuroscience Abstract Viewer and Itinerary
Planner 2013, 43.
12.
Salamone, J.D.; Nunes, E.J.; Randall, P.A.; Hart, E.E.; Freeland, C.; Yohn, S.E.; Lee,
C.A.; Nowak, V.; Baqi, Y.; Müller, C.E.; Lopez Cruz, L.; Correa, M. Development of
rodent models of the motivational symptoms of depression: The vesicular monamine
transport (VMAT-2) inhibitor tetrabenazine affects effort-related decision making in
rats. Society for Neuroscience Abstract Viewer and Itinerary Planner 2013, 43.
13.
Podurgiel, S.J.; Spencer, T.; Kovner, R.; Lopez-Cruz, L.; Pardo, M.; Baqi, Y.; Müller,
C.E.; Correa, M.; Salamone, J.D. Tremulous jaw movements induced by the
anticholinesterase galantamine: Studies with a mouse model of parkinsonian tremor.
Society for Neuroscience Abstract Viewer and Itinerary Planner 2013, 43.
14.
Baqi, Y.*; Scheiff, A.B.; Müller, C.E. Anthraquinone as a privileged structure in drug
discovery targeting P2Y receptors. Purinergic Signalling 2012, 8, 143–144.
15.
Hoffmann, K.; Lutz, D.; Baqi, Y.; Müller, C.E.; von Kügelgen, I. Involvement of
Cys194 in the interaction of the human platelet P2Y(12) receptor with Reactive Blue
2. Purinergic Signalling 2012, 8, 151–152.
16.
Batalha, V.L.; Valadas, J.S.; Baqi, Y.; Radjainia, H.; Müller, C.E.; Sebastiao, A.M.;
Lopes, L.V. Adenosine neuromodulation of hippocampal synaptic transmission in
12 | P a g e
Curriculum Vitae
Younis Baqi
chronic stress: Aging-like effect. Society for Neuroscience Abstract Viewer and
Itinerary Planner 2012, 42.
17.
Nunes, E.J.; Randall, P.A.; Freeland, C.; Hart, E.; Müller, C.E.; Baqi, Y.; Correa, M.;
Salamone, J.D. Development of rodent models of the motivational symptoms of
depression: The catecholamine depleting agent tetrabenazine affects effort-related
decision making in the concurrent FR5/chow choice task. Society for Neuroscience
Abstract Viewer and Itinerary Planner 2012, 42.
18.
Randall, P.A.; Nunes, E.J.; Pardo, M.; Khan, B.; Shah, P.; Lee, C.A.; Vemuri, V.K.;
Makriyannis, A.; Baqi, Y.; Müller, C.E.; Correa, M.; Salamone, J.D. Dissociable
effects of dopamine antagonists and cannabinoid CB1 antagonists: studies using the
concurrent progressive ratio/chow feeding task. Society for Neuroscience Abstract
Viewer and Itinerary Planner 2012, 42.
19.
Silva, C.G.; Metin, C.; Machado, N.J.; Darmopil, S.; Launay, P.; Ghestem, A.; Nesa,
M.-P.; Baqi, Y.; Müller, C.E.; Ivanov, A.; Zilberter, Y.; Cunha, R.A.; Bernard, C.;
Esclapez, M.T. Caffeine exposure during pregnancy disrupts GABAergic circuits in
offspring. Society for Neuroscience Abstract Viewer and Itinerary Planner 2012, 42.
20.
Yohn, S.E.; Nunes, E.J.; Randall, P.A.; Baqi, Y.; Müller, C.E.; Correa, M.; Salamone,
J.D. Development of rodent models of the motivational symptoms of depression: The
catecholamine depleting agent tetrabenazine affects effort-related decision making
in the T-maze barrier choice task. Society for Neuroscience Abstract Viewer and
Itinerary Planner 2012, 42.
21.
Podurgiel, S.J.; Kovner, R.; Barber, J.; Baqi, Y.; Müller, C.E.; Salamone, J.D.
Striatal dopamine depletion produced by the VMAT-2 inhibitor tetrabenazine induces
tremulous jaw movements: Implications for rodent models of parkinsonian tremor.
Society for Neuroscience Abstract Viewer and Itinerary Planner 2012, 42.
22.
Collins, L.E.; Paul, N.E.; Baqi, Y.; Müller, C.E.; Ledgard, F.; Satzer, D.; McPherson,
M.; Rhodes, C.; Senatus, P.B.; Salamone, J.D. Deep brain stimulation of the
subthalamic nucleus effectively reverses tremulous jaw movements induced by both
dopamine antagonism and cholinergic stimulation in a rodent model of Parkinsonian
tremor: Interaction with the effects of adenosine A2A antagonism. Society for
Neuroscience Abstract Viewer and Itinerary Planner 2011, 41.
23.
Kovner, R.; Randall, P.A.; Podurgiel, S.; Nunes, E.J.; Santerre, J.L.; Collins, L.E.;
Baqi, Y.; Müller, C.E.; Correa, M.; Salamone, J.D. Adenosine-dopamine interactions
in the open field arena: Studies related to locomotion and anxiety. Society for
Neuroscience Abstract Viewer and Itinerary Planner 2011, 41.
24.
Nunes, E.J.; Randall, P.A.; Santerre, J.L.; Fisher, J.; Correa, M.; Baqi, Y.; Müller,
C.E.; Salamone, J.D. Effort-related choice behavior is affected by pharmacological
manipulations associated with depression: Effects of reserpine. Society for
Neuroscience Abstract Viewer and Itinerary Planner 2011, 41.
25.
Pinna, A.; Costa, G.; Armentero, M.-T.; Baqi, Y.; Müller, C.E.; Franco, R.; Simola,
N. Antiparkinson activity of drugs acting on D-2-CB1-A(2A) receptors. Society for
Neuroscience Abstract Viewer and Itinerary Planner 2011, 41.
26.
Podurgiel, S.J.; Collins, L.E.; Pardo, M.; Baqi, Y.; Müller, C.E.; Schwarzschild, M.A.;
Correa, M.; Salamone, J.D. Adenosine A2A receptor knockout and pharmacological
antagonism reduced tremulous jaw movements: Studies with a mouse model of
13 | P a g e
Curriculum Vitae
Younis Baqi
parkinsonian tremor. Society for Neuroscience Abstract Viewer and Itinerary Planner
2011, 41.
27.
Randall, P.A.; Pardo, M.; Nunes, E.J.; Lopez-Cruz, L.; Blodgett, A.; Lingiah, K.;
Leser, C.; Vemuri, V.K.; Makriyannis, A.; Baqi, Y.; Müller, C.E.; Correa, M.;
Salamone, J.D. Effort-related choice behavior as assessed by a progressive
ratio/chow feeding task: Differential effects of DA D2 antagonism, adenosine A2A
antagonism, cannabinoid CB1 antagonism and pre-feeding. Society for Neuroscience
Abstract Viewer and Itinerary Planner 2011, 41.
28.
Santerre, J.L.; Nunes, E. J.; Randall, P.A.; Correa, M.; Baqi, Y.; Müller, C.E.;
Salamone, J.D. Behavioral and neurochemical characterization of the effects of the
novel adenosine A2A antagonist MSX-4. Society for Neuroscience Abstract Viewer
and Itinerary Planner 2011, 41.
29.
Baqi, Y.*; Hausmann, R.; Rosefort, C.; Schmalzing, G.; Müller, C.E. Development of
the first potent P2X2 receptor antagonist. Purinergic Signalling 2010, 6, 47–47.
30.
Santerre, J.L.; Nunes, E.J.; Randall, P.A.; Given, A.B.; Lee, C.A.; Baqi, Y.; Müller,
C.E.; Salamone, J.D. Interaction between Dopamine D2 receptor and adenosine A1
and A2A receptors: Studies of c-Fos immunoreactivity, behavioral activation and
effort related decision making. Society for Neuroscience Abstract Viewer and
Itinerary Planner 2010, 40.
31.
Baqi, Y.*; Atzler, K., Müller, C.E. High-affinity, non-nucleotide-derived competitive
antagonists of platelet P2Y12 receptors. Purinergic Signalling 2010, 6, 70–71.
32.
Hoffmann, K.; Baqi, Y.; Glänzel, M.; Müller, C.E.; von Kügelgen, I. Characterisation
of a new, very potent non-nucleotide antagonist acting at the human platelet P2Y 12
receptor and identification of its molecular site of interaction. Purinergic Signalling
2010, 6, 60–60.
33.
Hoffmann, K.; Baqi, Y.; Glänzel, M.; Müller, C.E.; von Kügelgen, I. Identification of
the site of interaction of new reactive blue 2-derived antagonists at the human
platelet P2Y12-receptor. Naunyn Schmiedeberg`s Arch Pharmacol. 2009, 379, Suppl
1:17–17.
34.
Baqi, Y.*; Weyler, S.; Hillmann, P.; Umbach, F.; Iqbal, J.; Kaulich, M.; Müller, C.E.
Anthraquinones: combinatorial synthesis and structure-activity relationships as nonnucleotide-derived P2Y2 receptor antagonists Purinergic Signalling 2008, 4, S13–
S13, Suppl. 1.
35.
Hoffmann, K.; Baqi, Y.; Müller, C.E.; von Kuegelelgen, I. Potent antagonistic action
of an analogue of reactive blue-2 at the human platelet P2Y12-receptor. Purinergic
Signalling 2008, 4, S20–S20, Suppl. 1.
36.
Iqbal, J.; Baqi, Y.; Weyler, S.; Zimmermann, H.; Müller, C.E. Anthraquinones:
structure-activity relationships as inhibitors of ecto-nucleoside triphosphate
diphospho-hydrolases (E-NTPDases). Purinergic Signalling 2008, 4, S106-S107,
Suppl. 1.
14 | P a g e
Curriculum Vitae
Younis Baqi
5.4– CONFERENCE ATTENDANCE
(Attended conferences are marked with "§", presenting author is marked with underline)
1.
Baqi, Y.§ Anthraquinone as a privileged scaffold in drug discovery targeting
nucleotide binding proteins. Purines2015 "International Conference on Purinergic
Signalling", July 23rd – 25th, Hamburg, Germany, 2015. (Invited Talk)
2.
Baqi, Y.§ Malik, E.M.; Fiene, A.; Lecka, A.; Sévigny, J.; Müller, C.E. Anthraquinone
Derivatives as Potent NTPDase2 inhibitors. Purines2015 "International Conference on
Purinergic Signalling", July 23rd – 25th, Hamburg, Germany, 2015. (Poster
Presentation)
3.
Baqi, Y.§ Design, synthesis and optimization of antagonists targeting A2A adenosine
receptors and A2A/CB1/D2 heteromeric GPCRs. 2nd Arab-American Frontiers of
Science, Engineering, and Medicine symposium, December 13-15, Muscat, Oman,
2014. (Invited Flash Talk)
4.
Baqi, Y.§ Anthraquinone as a privileged structure in drug discovery targeting
nucleotide binding proteins. The 4th International Conference of Young Scientists –
Chemistry Today (ICYS–2014), August 18th – 22nd, Yerevan, Armenia, 2014.
(Invited Talk)
5.
Brückner, M.; Schnaars, M.; Baqi, Y.§; Müller, C.E.; Halle, A. Microglia purinergic
receptors in Alzheimer’s disease. Purines 2014 “Nucleotides, Nucleosides and
Nucleobases International Conference on Signalling, Drugs and Targets”, July 23rd –
27th , Bonn, Germany, 2014. (Invited Talk)
6.
Malik, E.M.; Baqi, Y.§; Fiene, A.; Lecka, J.; Sévigny, J.; Müller, C.E. Design,
synthesis and structure-activity relationship of anthraquinone derivatives as
NTPDase3 inhibitors. Purines 2014 “Nucleotides, Nucleosides and Nucleobases
International Conference on Signalling, Drugs and Targets”, July 23 rd – 27th , Bonn,
Germany, 2014. (Poster Presentation)
7.
Pillaiyar, T.; Baqi, Y.§; Alshaibani, S.; Abdelrahman, A.; Namasivayam, V.;
Kostenis, E.; Müller, C.E. Design, synthesis and structure-activity relationship
studies of 4/6-substituted 2-carboxy-1H-indole-3-propionic acid derivatives as
GPR17 agonists. Purines 2014 “Nucleotides, Nucleosides and Nucleobases
International Conference on Signalling, Drugs and Targets”, July 23rd – 27th , Bonn,
Germany, 2014. (Poster Presentation)
8.
Rafehi, M.; Baqi, Y.§; Malik, E.M.; Müller, C.E. Anthraquinone derivatives as potent
and selective P2Y4 receptor antagonists. Purines 2014 “Nucleotides, Nucleosides and
Nucleobases International Conference on Signalling, Drugs and Targets”, July 23 rd –
27th , Bonn, Germany, 2014. (Poster Presentation)
9.
Spanier, C.; Baqi, Y.§; Malik, E.M.; Hausmann, R.; Müller, C.E. Structure-activity
relationships of anthraquinone derivatives as modulators of P2X3 receptors. Purines
2014 “Nucleotides, Nucleosides and Nucleobases International Conference on
Signalling, Drugs and Targets”, July 23rd – 27th , Bonn, Germany, 2014. (Poster
Presentation)
10.
Zhang, Y.; Baqi, Y.; Carlson, N.G.; Müller, C.E.; Kishore, B.K. Pharmacological
Blockade of P2Y12 Receptor in Rat IMCD Potentiates dDAVP-induced AQP2, AQP3 and
15 | P a g e
Curriculum Vitae
Younis Baqi
V2 Receptor Expression. Kidney Week 2013, November 5 th – 10th, Atlanta GA, USA,
2013. (Poster Presentation)
11.
Malik, E.M.; Baqi, Y.; Rafehi, M.; Müller, C.E. Design, synthesis, and structureactivity relationship of human P2Y4 receptor antagonists. Fifth Joint Italian-German
Purine Club Meeting – Fostering translational research on Purines by Italian-German
joint efforts. September 18th – 21st 2013, Rimini, Italy, 2013. (Poster Presentation)
12.
Blum, D.; Laurent, C.; Burnouf, S.; Ferry, B.; Batalha, V.; Marciniak, E.; Eddarkaoui,
S.; Basquin, M.; Parrot, S.; Demeyer, D.; Ledent, C.; Baqi, Y.; Müller, C.E.;
Hamdane, M.; Sergeant, N.; Humez, S.; Lopes, L.; Buee, L. A2A receptors as targets
in Alzheimer’s Disease: what about Tau pathology? Fifth Joint Italian-German Purine
Club Meeting – Fostering translational research on Purines by Italian-German joint
efforts. September 18th – 21st 2013, Rimini, Italy, 2013. (Invited Talk)
13.
Baqi, Y.§; Siebers, S.; Müller, C.E. Design, synthesis and optimization of antagonists
targeting A2A adenosine receptors and A2A/CB1/D2 heteromeric GPCRs. VIIIth Joint
Meeting on Medicinal Chemistry, June 30th – July 4th, 2013, Lublin, Poland, 2013.
(Invited Talk)
14.
Rafehi, M.; Baqi, Y.; Malik, E.M.; Müller, C.E. Developing a Potent and Selective
P2Y4-Receptor Antagonist. Frontiers in Medicinal Chemistry, March 17–20, 2013,
Munich, Germany, 2013. (Poster Presentation)
15.
Sperlagh, B.; Horváth, G.; Gölöncsér, F.; Csölle, C.; Király, K.; Andó, R.D.;
Hoffmann, K.; Algaier, I.; Baqi, Y.; Müller, C.E., Von Kügelgen, I. P2Y12 receptor
antagonists: A new approach for the treatment of inflammatory and neuropathic
pain. 5th International Conference on Drug Discovery and Therapy, February 18 –
21, 2013, Dubai, UAE, 2013. (Invited Talk)
16.
Baqi, Y.§; Zeck, A.; Malik, E.M.; Riedmaier, P.; Hartland, E.L., Müller, C.E. Design,
synthesis and structure-activity relationships of anthraquinone derivatives as
bacterial NTPDase inhibitors. Purines 2012, Adenine Nucleosides and Nucleotides in
Biomedicine ~ Purinergic Signalling in New Strategy of Drug Discovery ~, Fukuoka,
Japan, 2012. (Poster Presentation)
17.
Rafehi, M.; Baqi, Y.; Malik, E.M.; Müller, C.E. Structure-activity relationship study
for the development of a potent and selective P2Y4 receptor antagonist. 6th Summer
School Medicinal Chemistry, September 26th – 28th, 2012, Regensburg, Germany,
2012. (Oral Presentation)
18.
Rafehi, M.; Baqi, Y.; Malik, E.M.; Müller, C.E. Developing a potent and selective
P2Y4-receptor antagonist. DPhG-Doktorandentagung 2012, November 11th – 13th
2012, Weimar, Germany, 2012. (Oral Presentation)
19.
Baqi, Y.§; Müller, C.E. Design, synthesis and optimization of antagonists targeting
A2A/CB1/D2 heteromeric GPCRs. ERA-NET NEURON Meeting October 27 th – 28th,
Berlin, Germany, 2011. (Poster Presentation)
20.
Pinna, A.; Costa, G.; Armentero, M.-T.; Baqi, Y.§; Müller, C.E.; Franco, R.; Simola,
N. Antiparkinson activity of drugs acting on D2-CB1-A2A receptors. ERA-NET NEURON
Meeting October 27th – 28th, Berlin, Germany, 2011. (Invited Talk)
16 | P a g e
Curriculum Vitae
Younis Baqi
21.
Baqi, Y.§; Scheiff, A.B.; Müller, C.E. Anthraquinone as a privileged structure in drug
discovery targeting P2Y receptors. Fourth Joint German–Italian Purine Club Meeting
July 22nd – 25th 2011, Bonn, Germany, 2011. (Poster Presentation)
22.
Baqi, Y.§ Anthraquinone as a privileged structure in drug discovery targeting
nucleotide binding proteins. MED–CHEM Meeting April 15th – 16th, Leiden,
Netherland, 2011. (Invited Talk)
23.
Santerre, J.; Nunes, E.J.; Randall, P.A.; Baqi, Y.; Müller, C.E.; Salamone, J.D.
Behavioral studies with the novel adenosine A 2A antagonist MSX-4: reversal of the
effects of dopamine D2 antagonism. Neuroscience 2010, SfN's 40 th annual meeting,
Nov. 13–17, San Diego, CA, 2010. (Poster Presentation)
24.
Baqi, Y.§; Rosefort, C.; Hausmann, R.; Schmalzing, G.; Müller, C.E.; Discovery of
the first potent P2X2 receptor antagonists. Purines 2010, 30th May – 2nd June,
Tarragona-Barcelona, Spain, 2010. (Poster Presentation)
25.
Hoffmann, K.; Marine, E.; Baqi, Y.§; Müller, C.E.; von Kügelgen, I. Roles of highly
conserved amino acid residues of the human platelet P2Y 12-receptor in receptor
function and ligand recognition. Purines 2010, 30th May – 2nd June, TarragonaBarcelona, Spain, 2010. (Poster Presentation)
26.
Müller, C.E.; Hillmann, P.; Ko, G.–Y.; Baqi, Y.; Weyler, S.; Funke, M.; Scheiff, A.;
Sauer, R.; Höltje, H.–D. Medicinal chemistry of G protein-coupled UTP-activated
nucleotide receptors. Jahrestagung der Deutschen Pharmazeutischen Gesellschaft
e.V. Biotechnologisch erzeugte Wirkstoffe, Konzepte – Erfolge – Erwartungen. 28th
September – 1st October, Jena, Germany, 2009. (Invited Talk)
27.
Scheiff, A.B.; Baqi, Y.; Hillmann, P.; Müller, C.E. Anilinoanthraquinone derivatives
as P2Y receptor antagonists. Purines - 80 years and very much alive, 18th – 19th
September, Stockholm, Sweden, 2009. (Poster Presentation)
28.
Baqi, Y.§; Atzler, K.; Müller, C.E. High-affinity, non-nucleotide-derived competitive
antagonists of platelet P2Y12 receptors. Third Joint Italian-German Purine Club
Meeting Purinergic Receptors: New Frontiers for Novel Therapies, July 17 th – 20th,
Camerino, Italy, 2009. (Poster Presentation)
29.
Hoffmann, K.; Baqi, Y.§; Glänzel, M.; Müller, C.E.; von Kügelgen, I. Characterisation
of a new, very potent non-nucleotide antagonist acting at the human platelet P2Y 12receptor and identification of its molecular site of interaction.Third Joint ItalianGerman Purine Club Meeting Purinergic Receptors: New Frontiers for Novel
Therapies, July 17th – 20th, Camerino, Italy, 2009. (Oral Presentation)
30.
Baqi, Y.§; Weyler, S.; Hillmann, P.; Umbach, F.; Iqbal, J.; Kaulich, M.; Müller, C.E.
Anthraquinones: combinatorial synthesis and structure activity relationships as nonnucleotide-derived P2Y2 receptor antagonists. DPhG Tagung, 8th – 11th October,
Bonn, Germany, 2008. (Poster Presentation)
31.
Scheiff, A.B.; Baqi, Y.§; Hillmann, P.; Müller, C.E. Evaluation of anthraquinone
derivatives as P2Y receptor antagonists. DPhG Tagung, 8 th – 11th October, Bonn,
Germany, 2008. (Poster Presentation)
32.
Lehr, A.; Baqi, Y.§; Hoss, F.; Zimmermann, H.; Iqbal, J.; Müller, C.E. Testing of
novel ar(alk)ylaminoanthraquinone derivatives as inhibitors of ecto-5'-nucleotidase.
DPhG Tagung, 8th – 11th October, Bonn, Germany, 2008. (Poster Presentation)
17 | P a g e
Curriculum Vitae
Younis Baqi
33.
Iqbal, J.; Baqi, Y.§; Weyler, S.; Zimmermann, H.; Müller C.E. Selective nucleoside
triphosphate diphosphohydrolases (E-NTPDases) inhibitors identified by capillary
electrophoresis assay: anthraquinone derivatives derived from bromaminic acid.
DPhG Tagung, 8th – 11th, Bonn, Germany, 2008. (Poster Presentation)
34.
Hoffmann, K.; Baqi, Y.§; Müller, C.E.; von Kügelgen, I. Analysis of the interaction of
new non-nucleotide antagonists with the human platelet P2Y 12 receptor. DPhG
Tagung, 8th – 11th October, Bonn, Germany, 2008. (Poster Presentation)
35.
Müller, C.E.; Brunschweiger, A.; Baqi, Y.; Lee, S.-Y.; Iqbal, J.; Zimmermann, H.
Development of Ecto-5’-Nucleotidase Inhibitors as Potential New Anti-Cancer Drugs.
XX. International Symposium on Medicinal Chemistry EFMC-ISMC, 31st August – 4th
September, Vienna, Austria, 2008. (Poster Presentation)
36.
Baqi, Y.§; Weyler, S.; Hillmann, P.; Umbach, F.; Iqbal, J.; Kaulich, M.; Müller, C.E.
Anthraquinones: combinatorial synthesis and structure activity relationships as nonnucleotide-derived P2Y2 receptor antagonists. Purines, 29 th June – 2nd July,
Copenhagen, Denmark, 2008. (Poster Presentation)
37.
Iqbal, J.; Baqi, Y.§; Weyler, S.; Zimmermann, H.; Müllera C.E. Anthraquinones:
structure-activity relationships as inhibitors of ecto-nucleoside triphosphate
diphosphohydrolases (E-NTPDases). Purines, 29th June – 2nd July, Copenhagen,
Denmark, 2008. (Poster Presentation)
38.
Hoffmann, K.; Baqi, Y.§; Müller, C.E.; von Kügelgen, I. Potent antagonistic action of
an analogue of reactive blue-2 at the human platelet P2Y12 receptor. Purines, 29th
June – 2nd July, Copenhagen, Denmark, 2008. (Poster Presentation)
39.
Baqi, Y.§; Hillmann, P.; Scheiff, A.B.; Müller, C.E. General synthesis of
anthraquinone derivatives: development of non-nucleotide-derived P2Y2 receptor
antagonists. Second Joint Italian-German, Purine Club Meeting, 12th – 15th
September, Leipzig, Germany, 2007. (Poster Presentation)
40.
Baqi, Y.§; Iqbal, J.; Zimmermann, H.; Röllich, A.; Stephan, H.; Müller, C.E.
Polyoxometalates-discovery of a new class of ecto-nucleoside triphosphate
diphosphohydrolase (NTPDase) inhibitors. 3rd Summer School Medicinal Chemistry
at the University of Regensburg. “Medicinal Chemistry: Molecular Recognition-Ligand
Receptor Interactions”. 25th – 27th September, Regensburg, Germany, 2006. (Poster
Presentation)
41.
Baqi, Y.§; Iqbal, J.; Müller, C.E. Polyoxometalates – a new class of ecto-nucleoside
triphosphate diphosphohydrolase (NTPDase) inhibitors. Graduiertenkolleg 804,
Analyse von Zellfunktionen durch kombinatorische Chemie und Biochemie. BonnAachen International Center for Information Technology B–IT. University of Bonn,
Bonn, Germany, October 20th, 2006. (Poster Presentation)
5.5– GRANT & CONTRACT SUPPORT
(a)
Principal-Investigator
Funding Agency: His Majesty’s (HM) Research Grant
Grant Number: SR/SCI/CHEM/15/01
Duration: 2015–2018
Amount: 75,000 Omani Rials (equivalent to ~ 195,000 US dollars)
Title: Investigating the anti-cancer properties of natural products isolated from
date fruits of the Omani elite variety “Khalas”
18 | P a g e
Curriculum Vitae
Younis Baqi
(b)
Co-Principal-Investigator (PI: Osama Abou-Zied)
Funding Agency: The Research Council of Oman (TRC)
Grant Number: RC/SCI/CHEM/14/01
Duration: 2014–2017
Amount: 320,700 Omani Rials (equivalent to ~ 833,000 US dollars)
Title: Towards a better understanding of protein-ligand interaction: The role of
protein flexibility in ligand recognition, biological function, and drug binding
(c)
Co-Investigator (PI: Sarim Dastgir)
Funding Agency: His Majesty’s (HM) Research Grant
Grant Number: SR/SCI/CHEM/12/01
Duration: 2013–2016
Amount: 100,000 Omani Rials (equivalent to ~ 259,700 US dollars)
Title: “Production of Polyolefinic Materials via Coordination Polymerisation”
(d)
Principal and Sole Investigator
Funding Agency: Internal Grant (Sultan
Grant Number: IG/SCI/CHEM/13/02
Duration: 2013–2015
Amount: 8,250 Omani Rials (equivalent
Title: “Syntheses, Structure-Activity
Adenosine A2A Receptor Antagonists as
(e)
Qaboos University)
to ~ 21,500 US dollars)
Relationships, and Properties
Novel Anti-Parkinson Drugs”
of
New
Principal and Sole Investigator
Funding Agency: Internal Grant (Sultan Qaboos University)
Grant Number: IG/SCI/CHEM/16/04
Duration: 2016–2017
Amount: 2,000 Omani Rials (equivalent to ~ 5,200 US dollars)
Title: “Development of Xanthine Derivatives as Novel Adenosine A2A Receptor
Antagonists”
5.6– INTELLECTUAL PROPERTY DEVELOPMENT (PATENTS)
(a)
Kostenis, E.; Spinrath, A.; Hennen, S.; Peters, L.; Müller, C.E.; Akkari, R.; Baqi,
Y.; Ritter, K. GPR 17 Agonists and Screening Assay. US Patent 20,130,158,093.
For this patent we awarded “ZukunftErfindenNRW 2013 Award” (Inventions
for the Future) (http://www.ls-bt.de/index.php?article_id=875&clang=0)
(b)
Baqi, Y.; Müller, C.E. Novel P2Y12 receptor antagonists. EP Patent 2,129,653;
WO Patent 2,008,107,211.
For this patent a partial license agreement was given to
(http://www.tocris.com/dispprod.php?ItemId=268977#.UutYevl5PFI)
TOCRIS.
5.7– SCIENTIFIC VISITS AFTER JOINING SQU
(a)
Visiting Professor. Department of Pharmaceutical Chemistry, Pharmaceutical
Institute, University of Bonn, Germany, June 2012–Present: I have been invited
professor by the vice president of Bonn University for public relation and
collaboration (Prof. Dr. Christa E. Müller). During my frequent visits (six visits so
far, 3–8 weeks each), I have been involved as a group leader and supervised
undergraduate and post graduate students.
(b)
Visiting Professor. Division of Functional Genome Analysis, German Cancer
Research Center (Deutsches Krebsforschungszentrum (DKFZ), Heidelberg,
Germany. During my two visits (in 2013 & 2014), I successfully established
collaboration with the DKFZ which is helped in securing the HM grant that I won
this year (2015).
19 | P a g e